A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration

Annals of Emergency Medicine

Volumn 68, Issue 3, 2016, Pages 345-348

  Pahs, Lesley ^a   Droege, Chris ^a   Kneale, Hilary ^b   Pancioli, Arthur ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b ST JOHN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; ATORVASTATIN; DIPHENHYDRAMINE; FAMOTIDINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; METHYLPREDNISOLONE; TISSUE PLASMINOGEN ACTIVATOR; ANTIINFLAMMATORY AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST;

AGED; ANGIONEUROTIC EDEMA; ARTICLE; BRAIN ISCHEMIA; CASE REPORT; DISEASE ASSOCIATION; DISEASE COURSE; EMERGENCY WARD; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MALE; MEDICAL HISTORY; MEDICATION THERAPY MANAGEMENT; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OROLINGUAL ANGIOEDEMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TONGUE SWELLING; VITAMIN SUPPLEMENTATION; ANGIOEDEMA; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; INTRAVENOUS DRUG ADMINISTRATION; MOUTH DISEASES; TONGUE DISEASES;

AGED; ANGIOEDEMA; ANTI-INFLAMMATORY AGENTS; DIPHENHYDRAMINE; DRUG THERAPY, COMBINATION; FAMOTIDINE; HISTAMINE H1 ANTAGONISTS; HISTAMINE H2 ANTAGONISTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MOUTH DISEASES; TISSUE PLASMINOGEN ACTIVATOR; TONGUE DISEASES;

EID: 84975129072     PISSN: 01960644     EISSN: 10976760     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2016.02.019     Document Type: Article

References (22)

1. 1 Kaplan, A.P., Joseph, K., Silverberg, M., Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 109 (2002), 195–209.
2. 2 Walford, H.H., Zuraw, B.L., Current update on cellular and molecular mechanisms of hereditary angioedema. Ann Allergy Asthma Immunol 112 (2014), 413–418.
3. 3 Gorski, E.M., Schmidt, M.J., Orolingual angioedema with alteplase administration for treatment of acute ischemic stroke. J Emerg Med 45 (2013), e25–26.
4. 4 Miller, D.J., Simpson, J.R., Silver, B., Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies. Neurohospitalist 1 (2011), 138–147.
5. 5 Ottomeyer, C., Hennerici, M.G., Szabo, K., Raising awareness of orolingual angioedema as a complication of thrombolysis in acute stroke patients. Cerebrovasc Dis 27 (2009), 307–308.
6. 6 Engelter, S.T., Fluri, F., Buitrago-Tellez, C., et al. Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke. J Neurol 252 (2005), 1167–1170.
7. 7 Fugate, J.E., Kalimullah, E.A., Wijdicks, E.F., Angioedema after tPA: what neurointensivists should know. Neurocrit Care 16 (2012), 440–443.
8. 8 Rafii, M.S., Koenig, M., Ziai, W.C., Orolingual angioedema associated with ACE inhibitor use after rtPA treatment of acute stroke. Neurology, 65, 2005, 1906.
9. 9 Zarar, A., Khan, A.A., Adil, M.M., et al. Anaphylactic shock associated with intravenous thrombolytics. Am J Emerg Med 32 (2014), 113.e3–113.e5.
10. 10 Werner, R., Keller, M., Woehrle, J.C., Facial angioedema and stroke. Cerebrovasc Dis 38 (2014), 101–106.
11. 11 Hill, M.D., Lye, T., Barber, P.A., et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology 60 (2003), 1525–1527.
12. 12 Pancioli, A., Brott, T., Donaldson, V., et al. Asymmetric angioneurotic edema associated with thrombolysis for acute stroke. Ann Emerg Med 30 (1997), 227–229.
13. 13 Maertins, M., Wold, R., Swider, M., Angioedema after administration of rtPA for ischemic stroke: a case report. Air Med J 30 (2011), 276–278.
14. 14 Dromerick, A.W., Meschia, J.F., Kumar, A., et al. Simultaneous bilateral thalamic hemorrhages following the administration of intravenous tissue plasminogen activator. Arch Phys Med Rehabil 78 (1997), 92–94.
15. 15 Bas, M., Greve, J., Stelter, K., et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med 56 (2010), 278–282.
16. 16 Ismail, S., Cheng, L., Grigoriadou, S., et al. Lesson of the month 2: the limitations of steroid therapy in bradykinin-mediated angioedema attacks. Clin Med 15 (2015), 101–103.
17. 17 Lipski, S.M., Casimir, G., Vanlommel, M., et al. Angiotensin-converting enzyme inhibitors–induced angioedema treated by C1 esterase inhibitor concentrate (Berinert®): about one case and review of the therapeutic arsenal. Clin Case Rep 3 (2015), 126–130.
18. 18 Bova, M., Guilarte, M., Sala-Cunill, A., et al. Treatment of ACEI-related angioedema with icatibant: a case series. Intern Emerg Med 10 (2015), 345–350.
19. 19 Bas, M., Greve, J., Steiter, K., et al. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med 372 (2015), 418–425.
20. 20 Strassen, U., Bas, M., Hoffmann, T.K., et al. Treatment of angiotensin receptor blocker-induced angioedema: a case series. Laryngoscope 125 (2015), 1619–1623.
21. 21 Crowther, M., Bauer, K.A., Kaplan, A.P., The thrombogenicity of C1 esterase inhibitor (human): review of the evidence. Allergy Asthma Proc 35 (2014), 444–453.
22. 22 Gandhi, P.K., Gentry, W.M., Bottorff, M.B., Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 32 (2012), 902–909.